Sandoz readies Enbrel biosimilar for testing

Share this article:

The Enbrel biosimilar race just got tighter. Sandoz said Monday that it is launching Phase III trials of an etanercept biosimilar after hashing out the details with both European and US regulators.

The company said in a statement that it expects to use the global clinical trial results to support filings in both geographic areas for severe chronic plaque-type psoriasis. Enbrel is approved for moderate-to-severe plaque psoriasis, rheumatoid arthritis and psoriatic arthritis. Although the US has yet to establish a biosimilars approval protocol, the general feeling is that the rules are coming, and pharmaceutical pipelines are being readied to take advantage of the approval pathway once it does open.

Sandoz, Novartis' generics subsidiary, already has experience marketing biosimilars in the US, since an earlier drug got through via an alternate channel. The firm told MM&M in a prior interview that the lesson learned from launching that drug, growth hormone Omnitrope, was that biosimilar makers have to back the products with a support system that mimics that of a new-to-market drug as opposed to traditional generics, which have generally followed more of a linear, make-and-distribute sell pattern.

Enbrel has also been in the news lately because Amgen is preparing to dial back Pfizer's share of the royalties, when the US co-promotion agreement between the two firms ends later this year. The biologic, which earned about $4 billion in US sales last year, competes with the likes of AbbVie's multi-indication Humira, and much cheaper combinations of older medications, for those interested in lower-tech RA treatments.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.